Anti-Oral Mucositis Drug

Anti-Oral Mucositis Drug Market Outlook

The global anti-oral mucositis drug market is projected to reach approximately USD 1.5 billion by 2035, with a compound annual growth rate (CAGR) of around 8.5% during the forecast period from 2025 to 2035. The increasing prevalence of cancer and the rising number of people undergoing chemotherapy and radiation therapy are key factors contributing to this market growth. Oral mucositis is a common and debilitating side effect experienced by cancer patients as a result of these treatments, leading to significant discomfort and complications. In addition, innovations in drug formulations and delivery systems are enhancing the efficacy of treatments, while growing awareness of oral health in oncology is further driving demand. Additionally, the introduction of novel therapies and clinical trials aimed at addressing severe cases of oral mucositis are expected to create lucrative opportunities for market players.

Growth Factor of the Market

The growth of the anti-oral mucositis drug market is significantly driven by the rising incidences of cancer across the globe. Chemotherapy and radiotherapy, as standard treatments for cancer, often result in painful inflammation of the mucous membranes in the mouth, leading to oral mucositis. This condition not only affects patients' quality of life but also limits the delivery of cancer therapies due to associated pain and difficulty in eating or swallowing. Furthermore, increasing research and development activities focused on innovative drug solutions are paving the way for enhanced treatment options. The rising elderly population, who are more susceptible to cancer and its treatments, is also contributing to the market's expansion. Additionally, enhanced patient awareness regarding the importance of managing oral health during cancer treatment is driving the demand for effective anti-oral mucositis drugs.

Key Highlights of the Market

• Increased research and development in drug formulations specifically for oral mucositis treatment.
• Rising prevalence of cancer leading to a greater number of patients undergoing chemotherapy and radiotherapy.
• Growing awareness of oral health and its impact on cancer treatment outcomes.
• Introduction of effective treatments that enhance patient comfort and improve therapeutic adherence.
• Expanding distribution channels, including online pharmacies, enhancing accessibility for patients.

By Product Type

Oral Rinse:

Oral rinses are among the most commonly used products for managing oral mucositis, as they provide immediate relief from discomfort and help in maintaining oral hygiene. These solutions typically contain active ingredients that reduce inflammation, pain, and microbial load in the oral cavity. The ease of use and patient compliance associated with oral rinses make them popular, especially among patients undergoing cancer treatments. Furthermore, the growing number of prescription and over-the-counter oral rinse products tailored for mucositis management is propelling this segment forward, making it a critical component of the market.

Oral Gel:

Oral gels are viscous formulations designed to adhere to the mucosal surfaces inside the mouth, providing a protective barrier that helps alleviate pain and discomfort caused by mucositis. These gels often contain soothing agents and anti-inflammatory components, allowing for prolonged relief. The versatility of oral gels, combined with their ability to deliver therapeutic agents effectively, is driving their adoption among healthcare professionals and patients alike. The growing demand for localized treatment approaches that minimize systemic exposure to medications further enhances the appeal of oral gels in this market.

Oral Patch:

Oral patches are innovative drug delivery systems designed to adhere to the oral mucosa, providing localized treatment for mucositis. These patches release active ingredients gradually over time, ensuring sustained relief from pain and inflammation. The convenience of oral patches, which can be easily applied and require no additional preparation, contributes to their increasing popularity among patients. Moreover, advancements in patch technology, such as the development of bioadhesive formulations, are expected to drive this segment's growth further, making oral patches a significant contender in the anti-oral mucositis drug market.

Oral Spray:

Oral sprays offer a non-invasive and user-friendly solution for managing oral mucositis symptoms. They deliver active ingredients directly to the affected areas, making them suitable for patients who may have difficulty swallowing or using other dosage forms. The rapid absorption of sprays provides quick relief, which is particularly beneficial for patients experiencing severe discomfort. As healthcare providers increasingly recommend oral sprays for their ease of use and effectiveness, this segment is anticipated to witness significant growth in the coming years.

Oral Tablet:

Oral tablets represent a traditional method of drug delivery for mucositis treatment. While they may not offer the same localized relief as gels or patches, their systemic effects can be beneficial for managing pain associated with mucositis. The convenience of oral tablets, combined with the potential for combining multiple active ingredients in a single dosage form, makes them appealing to both patients and healthcare providers. The ongoing development of formulations that focus on minimizing side effects while maximizing therapeutic benefits is expected to sustain interest in oral tablets for mucositis management.

By Application

Hospitals:

Hospitals are critical settings for the administration of anti-oral mucositis drugs, as they provide complex care to cancer patients undergoing aggressive treatment regimens. The availability of specialized healthcare teams allows for effective management of mucositis symptoms and the implementation of comprehensive treatment protocols. Hospitals often have the necessary infrastructure to address severe cases of mucositis, thus making them the primary application sector for these drugs. The growing number of cancer patients treated in hospitals is propelling the demand for effective mucositis management solutions in this environment.

Cancer Treatment Centers:

Cancer treatment centers are specialized facilities that focus exclusively on delivering cancer therapies, and they are often equipped with multidisciplinary teams capable of managing complications like oral mucositis. The prevalence of oral mucositis among patients receiving chemotherapy and radiotherapy in these centers drives the demand for anti-mucositis drugs. These centers are at the forefront of clinical research, often participating in trials for new treatments, which further enhances the availability of innovative solutions for managing oral mucositis. As more patients seek specialized care in cancer treatment centers, the application of anti-oral mucositis drugs in these facilities is expected to grow significantly.

Research Institutes:

Research institutes play a vital role in advancing the understanding and treatment of oral mucositis. They conduct clinical trials to evaluate new therapeutic agents and treatment strategies aimed at alleviating symptoms. The collaboration between pharmaceutical companies and research institutes is crucial for developing innovative anti-oral mucositis drugs and determining their efficacy and safety. As the focus on research and development intensifies, the demand for anti-mucositis drugs in research settings is likely to see substantial growth, providing opportunities for market players to invest in new solutions.

Homecare Settings:

Homecare settings represent a growing application sector for anti-oral mucositis drugs, as patients increasingly seek to manage their symptoms at home to enhance their quality of life. The convenience of using oral rinses, gels, and sprays at home empowers patients to take charge of their mucositis management. The trend towards homecare is driven by the desire for comfort and autonomy among patients, especially those undergoing outpatient treatments. As a result, the development of user-friendly formulations and the expansion of distribution channels targeting homecare settings are expected to boost the market in this segment.

Others:

The 'Others' category encompasses various applications for anti-oral mucositis drugs, including palliative care facilities and long-term care facilities for patients with chronic conditions. These settings often have a significant population of individuals experiencing oral mucositis due to their medical conditions or treatments. The need for effective management of oral health in these facilities is driving demand for anti-mucositis drugs, contributing to market growth. Additionally, education and training for caregivers on managing mucositis effectively will further enhance the use of these products in diverse healthcare environments.

By Distribution Channel

Hospital Pharmacies:

Hospital pharmacies play a crucial role in the distribution of anti-oral mucositis drugs, as they cater specifically to the needs of hospitalized patients. These pharmacies ensure the availability of specialized medications that may not be found in retail settings, facilitating timely treatment for patients experiencing oral mucositis. The integrated approach of hospital pharmacies, which often involve a collaborative effort with medical teams, ensures that patients receive optimal care. With the increasing incidence of cancer and subsequent mucositis, hospital pharmacies are witnessing a steady growth in demand for these drugs.

Retail Pharmacies:

Retail pharmacies are an essential distribution channel for anti-oral mucositis drugs, offering accessible treatment options for patients managing symptoms at home or seeking relief between treatments. The convenience of retail pharmacies allows patients to obtain over-the-counter products, such as oral rinses and gels, without requiring a prescription. The competitive landscape among retail pharmacies also contributes to the availability of various brands and formulations, catering to diverse patient needs. The growing consumer awareness of oral care products is likely to boost sales in this segment, further driving market growth.

Online Pharmacies:

Online pharmacies have revolutionized the distribution of anti-oral mucositis drugs, providing a convenient and discreet option for patients. The rise of e-commerce in the pharmaceutical sector enables patients to order medications from the comfort of their homes, which is particularly beneficial for those with mobility challenges or those seeking to avoid crowded pharmacies. Online pharmacies often provide competitive pricing and home delivery services, enhancing their appeal to patients. As more consumers turn to online shopping for healthcare products, this distribution channel is expected to experience significant growth in the coming years.

Drug Stores:

Drug stores serve as traditional retail outlets for consumers seeking anti-oral mucositis drugs. These establishments often provide a wide selection of health-related products, including over-the-counter and prescription medications. The familiarity and accessibility of drug stores make them a popular choice for patients looking for quick relief from oral mucositis symptoms. Additionally, many drug stores offer consultation services, allowing patients to seek guidance from pharmacists on the appropriate products for their condition. The consistent foot traffic in drug stores contributes to the growth of this distribution channel in the anti-oral mucositis drug market.

Others:

The 'Others' category includes various niche distribution channels, such as specialty pharmacies and compounding pharmacies that focus on personalized medication solutions. Specialty pharmacies often cater to patients with specific medical needs, such as those suffering from severe oral mucositis, by providing tailored treatments that may not be available through conventional distribution channels. Compounding pharmacies can create customized formulations that address unique patient requirements, thus enhancing treatment options. As the demand for specialized care rises, these alternative distribution channels are expected to gain traction in the anti-oral mucositis drug market.

By Ingredient Type

Benzydamine:

Benzydamine is a widely utilized ingredient in anti-oral mucositis drugs due to its potent anti-inflammatory and analgesic properties. It is often formulated as an oral rinse or spray, providing relief from pain and discomfort associated with mucositis. Benzydamine works by reducing inflammation in the oral mucosa, thereby enhancing the quality of life for patients undergoing cancer treatments. Its efficacy and safety profile have made it a preferred choice among physicians, contributing to the growth of this ingredient segment in the anti-oral mucositis drug market.

Chlorhexidine:

Chlorhexidine is a broad-spectrum antiseptic used in various oral health applications, including the management of oral mucositis. Its antimicrobial properties help reduce bacterial load in the oral cavity, thus preventing secondary infections that can exacerbate mucositis symptoms. Chlorhexidine is commonly available in oral rinse formulations and is often recommended by healthcare professionals for its effectiveness. As awareness of oral hygiene and infection control in oncology settings grows, the demand for chlorhexidine-based products is expected to rise steadily.

Amifostine:

Amifostine is a cytoprotective agent that is used to mitigate the side effects of chemotherapy and radiotherapy, including oral mucositis. It works by scavenging free radicals, thereby protecting normal tissues from damage during cancer treatment. Amifostine is often administered intravenously but is increasingly being formulated for oral use to enhance patient convenience. The growing emphasis on supportive care in oncology is driving the demand for amifostine, highlighting its role in managing oral mucositis symptoms effectively.

Palifermin:

Palifermin is a recombinant human keratinocyte growth factor that has shown promise in preventing oral mucositis in high-risk cancer patients undergoing myeloablative chemotherapies. It promotes the proliferation of epithelial cells in the oral cavity, thereby enhancing mucosal integrity and reducing the incidence of mucositis. Palifermin's targeted approach to mitigating oral mucositis has garnered attention from healthcare providers, making it a significant contributor to the ingredient type segment. As more studies demonstrate its effectiveness, palifermin is poised for increased adoption in clinical settings.

Others:

The 'Others' category encompasses various ingredients used in the formulation of anti-oral mucositis drugs, including herbal extracts and natural compounds. These alternatives are gaining popularity among patients seeking holistic approaches to symptom management. Ingredients such as aloe vera and honey have shown potential in soothing oral mucositis symptoms and promoting healing. The increasing consumer preference for natural and alternative therapies is driving the growth of this segment, providing opportunities for manufacturers to explore innovative formulations that incorporate these ingredients.

By Region

In North America, the anti-oral mucositis drug market is anticipated to experience substantial growth, driven by the high prevalence of cancer and advanced healthcare infrastructure. The region is home to a significant number of cancer treatment centers and hospitals equipped to manage oral mucositis effectively. Moreover, increased patient awareness regarding oral health during cancer treatment is fostering demand for specialized products. The market in North America is projected to grow at a CAGR of around 8% during the forecast period, emphasizing the importance of developing effective therapies for oral mucositis.

Europe is also witnessing a growing demand for anti-oral mucositis drugs as the cancer burden rises in several countries. The European market benefits from robust healthcare systems and increased focus on research and development for innovative treatment solutions. The presence of key market players and ongoing clinical trials to test new formulations are expected to drive growth in this region. Furthermore, the emphasis on patient-centric care in European healthcare settings enhances the adoption of products that target oral health complications, contributing to the market's overall expansion.

Opportunities

One of the most significant opportunities in the anti-oral mucositis drug market lies in the development of novel treatment formulations that cater to specific patient needs. As research continues to uncover the complexities of oral mucositis, there is a growing potential for innovative solutions that improve patient comfort and adherence to cancer therapies. Companies are encouraged to invest in clinical trials that explore new ingredients and delivery mechanisms, such as mucoadhesive formulations or combination therapies that address multiple symptoms. Furthermore, collaborations between pharmaceutical companies and research institutes can lead to breakthroughs in treatment options, ultimately expanding market potential.

In addition to product innovation, the increasing prevalence of cancer, particularly in developing regions, presents a substantial market opportunity. As healthcare access improves and cancer screening programs expand globally, there will be a growing population of patients requiring effective oral mucositis management. Companies that establish distribution networks and partnerships in these emerging markets will be well-positioned to capture a share of the growing demand. Additionally, educational initiatives targeting both healthcare professionals and patients about the importance of managing oral mucositis can further drive awareness and consumption of these products.

Threats

Despite the promising growth prospects in the anti-oral mucositis drug market, certain threats could hinder its expansion. One of the primary challenges is the presence of alternative therapies and natural remedies that patients may prefer over traditional pharmaceutical options. As more individuals turn to holistic approaches for symptom relief, the market for conventional anti-mucositis drugs could face significant competition. Furthermore, regulatory hurdles related to the approval of new formulations can delay product launches and limit innovation in the market. Companies must navigate complex regulatory landscapes and demonstrate the safety and efficacy of their products to gain market access effectively.

Additionally, pricing pressures and reimbursement challenges may pose significant barriers to market growth. With increasing scrutiny on drug pricing and the demand for cost-effective treatment options, pharmaceutical companies may find it challenging to maintain competitive pricing while ensuring adequate profit margins. The potential for market consolidation among larger pharmaceutical companies could also limit the presence of smaller players, which may result in reduced diversity in treatment options available to patients. Companies must remain vigilant and responsive to these evolving market dynamics to sustain growth in the anti-oral mucositis drug sector.

Competitor Outlook

• Pfizer Inc.
• Amgen Inc.
• Merck & Co.
• Teva Pharmaceutical Industries Ltd.
• Novartis AG
• Eli Lilly and Company
• Bristol-Myers Squibb
• Hoffmann-La Roche Ltd.
• GlaxoSmithKline plc
• Sanofi S.A.
• Solvay Pharmaceuticals
• Gilead Sciences, Inc.
• Johnson & Johnson
• Actavis Plc
• Celgene Corporation

The competitive landscape of the anti-oral mucositis drug market is marked by the presence of several major players, each striving to gain a competitive edge through product development, strategic partnerships, and innovative marketing approaches. The market is characterized by a mix of established pharmaceutical companies and emerging players focusing on niche segments. Companies are increasingly investing in research and development to identify new formulations and delivery mechanisms that address the specific needs of patients suffering from oral mucositis. This focus on innovation, coupled with the growing number of clinical trials, is likely to enhance the market offerings and strengthen the competitive positioning of key players.

Leading companies such as Pfizer, Merck, and Amgen are at the forefront of the anti-oral mucositis drug market, leveraging their extensive experience in oncology and established distribution networks to reach healthcare professionals and patients effectively. For instance, Pfizer's research into mucoadhesive formulations has positioned it as a key player in providing targeted therapies for oral mucositis. Similarly, Merck's commitment to advancing supportive cancer therapies has resulted in the development of novel solutions tailored to manage mucositis symptoms. These industry giants are continually exploring strategic collaborations with research institutions to support the development of innovative treatment options and enhance their market presence.

Emerging companies are also making significant strides in the anti-oral mucositis drug market by focusing on targeted therapies and alternative ingredients that appeal to specific patient populations. For instance, companies exploring herbal remedies and natural ingredients are gaining traction, as more patients seek holistic approaches to managing their health. These players are often agile and can quickly adapt to emerging trends and consumer preferences, allowing them to carve out a niche within the competitive landscape. As the anti-oral mucositis drug market continues to evolve, the interplay between established firms and innovative newcomers will shape its future growth trajectory.

• 1 Appendix

  • 1.1 List of Tables
  • 1.2 List of Figures

• 2 Introduction

  • 2.1 Market Definition
  • 2.2 Scope of the Report
  • 2.3 Study Assumptions
  • 2.4 Base Currency & Forecast Periods

• 3 Market Dynamics

  • 3.1 Market Growth Factors
  • 3.2 Economic & Global Events
  • 3.3 Innovation Trends
  • 3.4 Supply Chain Analysis

• 4 Consumer Behavior

  • 4.1 Market Trends
  • 4.2 Pricing Analysis
  • 4.3 Buyer Insights

• 5 Key Player Profiles

  • 5.1 Amgen Inc.
    • 5.1.1 Business Overview
    • 5.1.2 Products & Services
    • 5.1.3 Financials
    • 5.1.4 Recent Developments
    • 5.1.5 SWOT Analysis
  • 5.2 Actavis Plc
    • 5.2.1 Business Overview
    • 5.2.2 Products & Services
    • 5.2.3 Financials
    • 5.2.4 Recent Developments
    • 5.2.5 SWOT Analysis
  • 5.3 Merck & Co.
    • 5.3.1 Business Overview
    • 5.3.2 Products & Services
    • 5.3.3 Financials
    • 5.3.4 Recent Developments
    • 5.3.5 SWOT Analysis
  • 5.4 Novartis AG
    • 5.4.1 Business Overview
    • 5.4.2 Products & Services
    • 5.4.3 Financials
    • 5.4.4 Recent Developments
    • 5.4.5 SWOT Analysis
  • 5.5 Pfizer Inc.
    • 5.5.1 Business Overview
    • 5.5.2 Products & Services
    • 5.5.3 Financials
    • 5.5.4 Recent Developments
    • 5.5.5 SWOT Analysis
  • 5.6 Sanofi S.A.
    • 5.6.1 Business Overview
    • 5.6.2 Products & Services
    • 5.6.3 Financials
    • 5.6.4 Recent Developments
    • 5.6.5 SWOT Analysis
  • 5.7 Johnson & Johnson
    • 5.7.1 Business Overview
    • 5.7.2 Products & Services
    • 5.7.3 Financials
    • 5.7.4 Recent Developments
    • 5.7.5 SWOT Analysis
  • 5.8 Celgene Corporation
    • 5.8.1 Business Overview
    • 5.8.2 Products & Services
    • 5.8.3 Financials
    • 5.8.4 Recent Developments
    • 5.8.5 SWOT Analysis
  • 5.9 GlaxoSmithKline plc
    • 5.9.1 Business Overview
    • 5.9.2 Products & Services
    • 5.9.3 Financials
    • 5.9.4 Recent Developments
    • 5.9.5 SWOT Analysis
  • 5.10 Bristol-Myers Squibb
    • 5.10.1 Business Overview
    • 5.10.2 Products & Services
    • 5.10.3 Financials
    • 5.10.4 Recent Developments
    • 5.10.5 SWOT Analysis
  • 5.11 Eli Lilly and Company
    • 5.11.1 Business Overview
    • 5.11.2 Products & Services
    • 5.11.3 Financials
    • 5.11.4 Recent Developments
    • 5.11.5 SWOT Analysis
  • 5.12 Gilead Sciences, Inc.
    • 5.12.1 Business Overview
    • 5.12.2 Products & Services
    • 5.12.3 Financials
    • 5.12.4 Recent Developments
    • 5.12.5 SWOT Analysis
  • 5.13 Hoffmann-La Roche Ltd.
    • 5.13.1 Business Overview
    • 5.13.2 Products & Services
    • 5.13.3 Financials
    • 5.13.4 Recent Developments
    • 5.13.5 SWOT Analysis
  • 5.14 Solvay Pharmaceuticals
    • 5.14.1 Business Overview
    • 5.14.2 Products & Services
    • 5.14.3 Financials
    • 5.14.4 Recent Developments
    • 5.14.5 SWOT Analysis
  • 5.15 Teva Pharmaceutical Industries Ltd.
    • 5.15.1 Business Overview
    • 5.15.2 Products & Services
    • 5.15.3 Financials
    • 5.15.4 Recent Developments
    • 5.15.5 SWOT Analysis

• 6 Market Segmentation

  • 6.1 Anti-Oral Mucositis Drug Market, By Application
    • 6.1.1 Hospitals
    • 6.1.2 Cancer Treatment Centers
    • 6.1.3 Research Institutes
    • 6.1.4 Homecare Settings
    • 6.1.5 Others
  • 6.2 Anti-Oral Mucositis Drug Market, By Product Type
    • 6.2.1 Oral Rinse
    • 6.2.2 Oral Gel
    • 6.2.3 Oral Patch
    • 6.2.4 Oral Spray
    • 6.2.5 Oral Tablet
  • 6.3 Anti-Oral Mucositis Drug Market, By Ingredient Type
    • 6.3.1 Benzydamine
    • 6.3.2 Chlorhexidine
    • 6.3.3 Amifostine
    • 6.3.4 Palifermin
    • 6.3.5 Others
  • 6.4 Anti-Oral Mucositis Drug Market, By Distribution Channel
    • 6.4.1 Hospital Pharmacies
    • 6.4.2 Retail Pharmacies
    • 6.4.3 Online Pharmacies
    • 6.4.4 Drug Stores
    • 6.4.5 Others

• 7 Competitive Analysis

  • 7.1 Key Player Comparison
  • 7.2 Market Share Analysis
  • 7.3 Investment Trends
  • 7.4 SWOT Analysis

• 8 Research Methodology

  • 8.1 Analysis Design
  • 8.2 Research Phases
  • 8.3 Study Timeline

• 9 Future Market Outlook

  • 9.1 Growth Forecast
  • 9.2 Market Evolution

• 10 Geographical Overview

  • 10.1 Europe - Market Analysis
    • 10.1.1 By Country
      • 10.1.1.1 UK
      • 10.1.1.2 France
      • 10.1.1.3 Germany
      • 10.1.1.4 Spain
      • 10.1.1.5 Italy
  • 10.2 Asia Pacific - Market Analysis
    • 10.2.1 By Country
      • 10.2.1.1 India
      • 10.2.1.2 China
      • 10.2.1.3 Japan
      • 10.2.1.4 South Korea
  • 10.3 Latin America - Market Analysis
    • 10.3.1 By Country
      • 10.3.1.1 Brazil
      • 10.3.1.2 Argentina
      • 10.3.1.3 Mexico
  • 10.4 North America - Market Analysis
    • 10.4.1 By Country
      • 10.4.1.1 USA
      • 10.4.1.2 Canada
  • 10.5 Middle East & Africa - Market Analysis
    • 10.5.1 By Country
      • 10.5.1.1 Middle East
      • 10.5.1.2 Africa
  • 10.6 Anti-Oral Mucositis Drug Market by Region

• 11 Global Economic Factors

  • 11.1 Inflation Impact
  • 11.2 Trade Policies

• 12 Technology & Innovation

  • 12.1 Emerging Technologies
  • 12.2 AI & Digital Trends
  • 12.3 Patent Research

• 13 Investment & Market Growth

  • 13.1 Funding Trends
  • 13.2 Future Market Projections

• 14 Market Overview & Key Insights

  • 14.1 Executive Summary
  • 14.2 Key Trends
  • 14.3 Market Challenges
  • 14.4 Regulatory Landscape

Segments Analyzed in the Report

The global Anti-Oral Mucositis Drug market is categorized based on

By Product Type

• Oral Rinse
• Oral Gel
• Oral Patch
• Oral Spray
• Oral Tablet

By Application

• Hospitals
• Cancer Treatment Centers
• Research Institutes
• Homecare Settings
• Others

By Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
• Drug Stores
• Others

By Ingredient Type

• Benzydamine
• Chlorhexidine
• Amifostine
• Palifermin
• Others

By Region

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East & Africa

Key Players

• Pfizer Inc.
• Amgen Inc.
• Merck & Co.
• Teva Pharmaceutical Industries Ltd.
• Novartis AG
• Eli Lilly and Company
• Bristol-Myers Squibb
• Hoffmann-La Roche Ltd.
• GlaxoSmithKline plc
• Sanofi S.A.
• Solvay Pharmaceuticals
• Gilead Sciences, Inc.
• Johnson & Johnson
• Actavis Plc
• Celgene Corporation